Olink provides deCODE genetics access to protein analysis platform

Published: 14-Jul-2021

deCODE will be one of the first companies to adopt and internalise the platform and will act as an early testing site for its use

deCODE genetics, an Amgen subsidiary which focuses on analysing the human genome, has signed an agreement with Olink Holdings to gain internal access to the company’s Explore 3072 platform, comprised of approximately 3,000 high quality protein assays with a next generation sequencing (NGS) read-out.

deCODE will be one of the first companies to adopt and internalise the platform and will act as an early testing site for its use. The companies will work together to optimise Olink’s large-scale proteomics efforts.

“We are proud to work closely with deCODE genetics’ world-class genomic and pharmaceutical scientists”, said Jon Heimer, CEO of Olink. “They have a very impressive track record of providing insights to enhance the vital research into the most common and life-threatening diseases. We believe this agreement demonstrates the accelerating trend to continue to connect the wealth of available genomic data with actionable proteomics. We see deCODE genetics as an exceptional early-access site for the Olink Explore 3072 platform.”

Olink intends to make the Olink Explore 3072 high quality protein assay platform broadly available in the fourth quarter of 2021.

“We believe our carefully curated and validated library of assays, based on our proprietary and patented PEA technology, has the foundation necessary for broad application in large scale discovery as well as more targeted clinical trials and diagnostic applications. We intend to enable our customers to make faster, better-informed scientific decisions by providing this scalable platform for quantification of protein biomarkers in a high-multiplex and high-throughput format. And, of the utmost importance, with assay performance that does not compromise on data quality. We share our customers´ excitement about the expansion of our protein biomarker targets and about making it available to more users around the world through our reagent kits”, said Jon Heimer.

You may also like